Colonoscopy Clinical Trial
Official title:
Multicenter Clinical Trial for the Evaluation of Safety and Effectiveness of Endorail in Patients With Long-lasting Colonoscopy
NCT number | NCT05626738 |
Other study ID # | Endorail |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | January 25, 2023 |
Est. completion date | July 24, 2023 |
Verified date | July 2023 |
Source | Endostart srl |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Patients with long lasting colonoscopy are characterized by higher risk of incompletion. Endorail is an accessory for colonoscopy aimed at facilitating progression of the endoscope in the large intestine. Endorail works as a magnetic anchor that is able to guide the colonoscope and to straighten colon curves and loops. The aim of this study is to test the safety and efficacy of Endorail in ensuring that incompletion rate in long-lasting colonoscopies is lower than the 10% threshold. Outpatients of either sex aged between 22-75 years undergoing elective diagnostic or surveillance colonoscopy with caecal intubation time greater than 10 minutes will take part in the study. The primary efficacy endpoint is the percentage minor or equal to 10% of incomplete long-lasting colonoscopies. The primary safety endpoints are the absence of device-related serious adverse events and the evaluation of the equality or reduction of the adverse events rates compared to diagnostic colonoscopies without Endorail.
Status | Completed |
Enrollment | 38 |
Est. completion date | July 24, 2023 |
Est. primary completion date | May 24, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 22 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Patients of both sexes aged between 22 - 75 years (inclusive); 2. Outpatients undergoing long-lasting diagnostic and surveillance colonoscopy; long-lasting colonoscopy is defined as follows: colonoscopy completion (caecal intubation) not achieved after 10 minutes from endoscope insertion through the anal canal; 3. Patients have given a written informed consent for participation in the study at the time of enrolment or before; 4. Patients able to understand the full nature and the purpose of the investigation, including possible risks and side effects, able to cooperate with the Investigator and to comply with the requirements of the entire investigation based on Investigator's judgement. Exclusion Criteria: 1. Body mass index (BMI) > 30 kg/m2; 2. Outpatients undergoing colonoscopy for colorectal cancer screening or therapeutic indication; 3. Patients in class >2 physical status of the classification system of American Society of Anaesthesiologists; 4. Any contraindications to colonoscopy; 5. Any contraindications to sedation; 6. Known allergy or hypersensitivity to any of the elements of the Endorail Set (e.g.: iron); 7. Patients with permanently or semi-permanently implanted medical devices, (e.g. orthopedic implants, trauma fixation devices, cardiac pacemakers, implantable cardioverter defibrillator, drug pumps, neurostimulators, vascular stents, cochlear implants, aneurysm clip); 8. Presence of dense diverticulosis 9. Presence of diverticulitis 10. Presence of ferromagnetic foreign body; 11. Presence of large abdominal hernias; 12. Presence of severe thrombocytopenia; 13. Presence of severe granulocytopenia; 14. Presence of severe coagulopathy; 15. Presence of peritonitis; 16. Presence of colonic wall ischemia or necrosis or injured mucosa; 17. Presence of peritoneal carcinomatosis; 18. Boston Bowel Preparation Scale <2 in at least one of the colonic segments; 19. Presence of obstructing masses and strictures of the colon; 20. History of total or subtotal colectomy. 21. Presence of angulated and fixed colon curves; 22. Pregnant or breast-feeding women; 23. Patient unable to provide the signed informed consent, uncooperative patient or patient unlikely to comply with the protocol or unable to understand the nature, scope and possible consequences of the study; 24. Presence of any other reason that, in the opinion of the investigator, prevents the subject from participating in the study or compromises the subject safety 25. Concomitant participation in other clinical investigations or participation in the evaluation of any investigational product/device in the 30 days before this study or previous participation in the same investigation; 26. Urgent colonoscopy. |
Country | Name | City | State |
---|---|---|---|
Belgium | University Hospitals | Leuven | |
Germany | Gastrozentrum | Lippe | |
Italy | Humanitas | Milano |
Lead Sponsor | Collaborator |
---|---|
Endostart srl |
Belgium, Germany, Italy,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Evaluation of Endorail efficacy | The percentage minor or equal to 10% of incomplete long-lasting colonoscopies (colonoscopy is defined completed when caecal intubation is achieved) | day 1 | |
Primary | Evaluation of Endorail safety | The absence of device-related serious adverse events will be collected during the treatment | day 1 | |
Primary | Evaluation of Endorail safety | The absence of device-related serious adverse events will be collected through phone call after 7 days of procedure | day 7 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04101097 -
Training and Validation of Models of Factors to Predict Inadequate Bowel Preparation Colonoscopy
|
||
Completed |
NCT03247595 -
Testing How Well Magnesium Citrate Capsules Work as Preparation for a Colonoscopy
|
N/A | |
Completed |
NCT04214301 -
An Open-Label Preference Evaluation of BLI800
|
Phase 4 | |
Withdrawn |
NCT05754255 -
Comparison of High-flow Oxygen With or Without Nasal Positive Airway Pressure (PAP) During Propofol Sedation for Colonoscopy in an Ambulatory Surgical Center
|
N/A | |
Recruiting |
NCT02484105 -
Comforting Conversation During Colonoscopy: A Trial on Patient Satisfaction
|
Phase 4 | |
Active, not recruiting |
NCT02264249 -
Residual Gastric Volume in Same Day Versus Split Dose and Evening Before Bowel Preparation
|
N/A | |
Terminated |
NCT01978509 -
The Affect of Low-Volume Bowel Preparation for Hospitalized Patients Colonoscopies
|
N/A | |
Completed |
NCT01964417 -
The Comparative Study Between Bowel Preparation Method
|
Phase 3 | |
Recruiting |
NCT01685970 -
Comparison of Same-day 2 Sachets Picosulfate Versus High Volume PEG for Afternoon Colonoscopy
|
Phase 3 | |
Completed |
NCT01518790 -
Short Course, Single-dose PEG 3350 for Colonoscopy Prep in Children
|
N/A | |
Recruiting |
NCT00748293 -
Achievement of Better Examinee Compliance on Colon Cleansing Using Commercialized Low-Residue Diet
|
N/A | |
Completed |
NCT00779649 -
MoviPrep® Versus HalfLytely®, Low-VolUme PEG Solutions for Colon Cleansing: An InvesTigator-blindEd, Randomized, Trial
|
Phase 4 | |
Completed |
NCT00671177 -
Clinical Evaluation of Water Immersion Colonoscopy Insertion Technique
|
N/A | |
Completed |
NCT00380497 -
Pico-Salax Versus Poly-Ethylene Glycol for Bowel Cleanout Before Colonoscopy in Children
|
Phase 4 | |
Recruiting |
NCT00160823 -
Impact of a Self-Administered Information Leaflet on Adequacy of Colonic Cleansing for in-Hospital Patients
|
Phase 3 | |
Completed |
NCT00314418 -
Patient Position and Impact on Colonoscopy Time
|
N/A | |
Completed |
NCT00390598 -
PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy
|
Phase 2/Phase 3 | |
Completed |
NCT00209573 -
A Study of AQUAVAN® Injection Versus Midazolam HCl for Sedation in Patients Undergoing Elective Colonoscopy
|
Phase 3 | |
Completed |
NCT00427089 -
Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
|
Phase 3 | |
Completed |
NCT05823350 -
The Effect of Abdominal Massage on Pain and Distention After Colonoscopy
|
N/A |